A US health economist has argued that the latest round of discount prescription drug prices (Marketletter May 12) recently announced by Wal-Mart, the largest retailer by sales, is part of a strategy to move into "the lucrative turf" of pharmacy benefit managers. Jane Sarasohn-Kahn, founder of a consultancy firm, THINK-Health, argues that the $10 for a 90-day supply of certain generic medicines "puts Wal-Mart firmly in the pharmacy benefits management segment vis-a-vis ExpressScripts, Medco and the [other] big PBM players."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze